THY-Tau22 mice are a model for tau aggregation, a pathological hallmark of Alzheimer's disease as well as numerous tauopathies. With age these mice develop a variety of tau-related neuropathological ...

This approach uses mesenchymal stem cells isolated from a patient’s own fat tissue to treat neurodegenerative diseases. The stem cells are supposed to assist in repair of damaged tissue and ...

Species: Mouse Genes: SNCA Modification: SNCA: Transgenic Disease Relevance: Parkinson's Disease Strain Name: B6;DBA-Tg(Thy1-SNCA)61Ema Genetic Background: (C57BL/6 x DBA/2)F1 (strain of origin) ...

Blood draws from across sub-Saharan Africa are underway. Samples are shipped from Nigeria to Miami. There, their genetics and biomarkers are being analyzed. According to the most recent Global Burden ...

A selected list of scientific conferences relevant to researchers, clinicians and others interested in Alzheimer’s disease and related neurodegenerative disorders.

It’s official: A new AI consortium to speed the pace of discoveries in AD research is off to the races. Its name? C-brAIn, emphasis evoking artificial intelligence intended. Alzforum first reported on ...

The current Alzheimer’s disease therapeutic antibodies carry a sizable risk of ARIA, especially for APOE4 carriers. Researchers believe the future of amyloid immunotherapies lies in targeted brain ...

The highly selective border lining the brain’s vasculature is the Achilles’ heel of any large therapeutic molecule aiming for targets in the brain, anti-Aβ antibodies included. Not only do fewer than ...

visualizes axons in an area-specific maturation patternin human fetal brain; visualizes aberrantly sprouting axons in neuriticplaques derived from cortico-cortical fibers in A.D. and identifies loss ...

Many people with Alzheimer’s notice their sense of smell isn’t as sharp as it used to be long before their memory declines. The underlying mechanisms responsible for this change have remained a ...

reactivity depends on both the N terminus (amino acids 7–9), and an amino acid sequence of tau (amino acids 313–322) in the third microtubule binding domain. Recognizes neurofibrillary tangles but ...

The therapeutic antibody lecanemab has been in clinical use in the U.S. for two years, and doubts about whether it would be feasible for clinics to implement and manage this therapy have eased. Even ...